Photo taken from Agenus/LinkedIn
May 12, 2024, 03:08
CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals
Agenus shared on LinkedIn:
“‘With this infusion of capital, we are poised to accelerate the development of our lead therapeutic combination regimen, botensilimab/balstilimab, which we expect to make a significant impact in the treatment of MSS colorectal cancer.
This initiative brings us closer to our goal of dramatically improving cancer treatment for patients who are often left with limited or no options.’
Chairman and CEO Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals.”
Additional information.
Source: Agenus/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08